Compare Charles River Laboratories Intl. Inc (CRL) vs 8x8 Inc (EGHT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs 8x8 Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $231 (market cap $11.14B), while 8x8 Inc trades at $2.17 (market cap $309.09M). The key difference: Charles River Laboratories Intl. Inc is far larger — about 36× 8x8 Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, 8x8 Inc nearer its low. Which is the better fit depends on your goals.
| CRL | EGHT | |
|---|---|---|
Market Cap | $11.14B | $309.09M |
Sector | Health | Technology |
52-Week High | $233.60 | $2.76 |
52-Week Low | $145.57 | $1.59 |
Enterprise Value | $14.00B | $586.76M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
EGHT trades at $2.22, up 8.29% with strong technical momentum and bullish moving averages. The company shows improving fundamentals with three consecutive quarterly EPS beats and projected profitability in 2026. Recent product innovations in AI routing and workforce management demonstrate growth potential, though high P/E ratio of 218 and negative net income require careful valuation assessment.
EGHT presents a turnaround story with improving earnings momentum and AI-driven product expansion, but faces significant execution risks amid high valuation multiples. The stock's technical strength contrasts with fundamental challenges, requiring balanced risk-reward evaluation for investors seeking growth opportunities in communications technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →
